We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 57

Data protection in Canada: too much? Too little?
  • Gowling WLG
  • Canada
  • June 28 2011

Prior to the enactment in 2006 of the amendments to section C.08.004.1 of the Food and Drugs Regulations (Data Protection Regulations), Canada did not have an effective regime of data protection exclusivity.


Two amendments to pharma legislation come into force
  • Gowling WLG
  • Canada
  • April 14 2011

The Amendments to The Food and Drug Regulations (1319- New Drugs For Extraordinary Use) came into force on March 25, 2011.


Europe wants Canada to update patent laws
  • Gowling WLG
  • Canada, European Union
  • March 15 2011

Canada is currently negotiating a comprehensive economic trade agreement with the European Union to increase the volume of trade and business occurring between Canada and Europe.


Board follows guidelines in Penlac decision
  • Gowling WLG
  • Canada
  • February 7 2011

On February 3, 2011, the Patented Medicine Prices Review Board (the Board) released its decision dated January 31, 2011, regarding Penlac, a drug manufactured by sanofi-aventis.


A licensing regime for food importers?
  • Gowling WLG
  • Canada
  • January 14 2011

The Canadian Food Inspection Agency (CFIA) is considering adopting a licensing regime that would apply to all importers of food products or food ingredients in the non-federally registered sector (NFRS).


Generic drug companies complain about lower prices
  • Gowling WLG
  • Canada
  • September 21 2010

As reported on September 13, 2010 in the National Post, representatives of Canadian generic companies, including Apotex, Teva and the Canadian Generic Pharmaceutical Association are warning that lower prices for generic medicines could backfire.


Provinces and territories discuss joining forces to purchase drugs at lower prices
  • Gowling WLG
  • Canada
  • August 26 2010

On August 6, 2010, Canadian Premiers attended their annual Council of the Federation Premiers' Conference in Winnipeg to discuss a joint alliance among the provinces and territories for purchasing common drugs and medical supplies and equipment for the public sector.


Case comment: Glaxosmithkline Inc. (FCA) - elusive valuations of bundled transactions: defining a standard of reasonableness in transfer pricing
  • Gowling WLG
  • Canada
  • August 4 2010

The task of making valuations for transfer pricing involving bundled transactions has always been a daunting one.


New decision on freedom of information re: product listing agreements
  • Gowling WLG
  • Canada
  • July 13 2010

On June 28, 2010, the Information and Privacy Commissioner of Ontario released a decision in Appeal Number PA08-294-2, which pertains to disclosure of Schedules to a product listing agreement between an unidentified drug company (the "affected party") and the Executive Officer of the Ontario Public Drug Programs ("OPDP").


First PMPRB decision dismissing allegations of excessive pricing
  • Gowling WLG
  • Canada
  • April 20 2010

The Patented Medicine Prices Review Board ("PMPRB") recently released its decision in the matter of Hoechst Marion Roussel Canada Inc. and the medicine NIOCODERM, a nicotine patch which assists those who are attempting to quit smoking; it is to be publicly posted on the PMPRB website today.